These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2005-005406-24 Phase III multicentric IIL study, three randomized arms (R-CVP vs R-CHOP vs R-FM),for treatment of patients with stage II-IV follicular lymphoma bad-data
Not reported 2009-012337-29 Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma 2015-01-26 due-trials
Completed, but no date 2010-019248-37 A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s Lymphoma bad-data
Ongoing 2011-000175-13 A phase II study of oral Panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma after high-dose chemotherapy with autologous stem cell transfusion (ASCT) or in adult pa... not-yet-due
Ongoing 2011-001421-24 Rituximab plus Bendamustine as front line treatment in frail elderly (≥70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linf... not-yet-due
Not reported 2011-003191-36 Dose-dense ABVD as first line therapy in early stage unfavorable Hodgkin’s Lymphoma: a phase II, prospective, multi-center study 2017-04-29 due-trials
Ongoing 2011-003769-14 R-CHOP-14 or R-CHOP-21 & consolidation PET–oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1) not-yet-due
Ongoing 2011-005461-21 BENDAMUSTINE, LENALIDOMIDE AND RITUXIMAB (R2-B)COMBINATION AS A SECOND-LINE THERAPY FOR FIRST RELAPSED-REFRACTORY MANTLE CELL LYMPHOMAS: A PHASE II STUDY not-yet-due
Ongoing 2011-005739-23 Phase II study of age‐adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL) not-yet-due
Ongoing 2012-000251-14 A PHASE III MULTICENTER, RANDOMIZED STUDY COMPARING CONSOLIDATION WITH (90)YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) RADIOIMMUNOTHERAPY VS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS... not-yet-due
Completed, but no date 2012-000735-27 A phase II study of SGN-35 (brentuximab vedotin) of patients with relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL). bad-data
Ongoing 2012-000924-16 Phase II randomized study with R-DHAP +/- Bortezomib as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem ... not-yet-due
Ongoing 2012-001404-38 Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. not-yet-due
Ongoing 2012-001676-11 "MIRO" study (Molecularly Oriented Immuno-radio-therapy): a multicenter phase II trail for the treatment on molecular basis of stage I / II Follicular Lymphoma with local radiotherapy with / without ... not-yet-due
Ongoing 2012-003170-60 A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Ly... not-yet-due
Ongoing 2012-003392-18 A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-... not-yet-due
Ongoing 2013-003256-20 A PHASE II PROSPECTIVE STUDY OF HIGH-DOSE myeloablative therapy, WITH STEM CELL DEVICES SUPPORT IN ELDERLY PATIENTS (from 65 to 76 years) with relapsed aggressive non-Hodgkin lymphoma OR RESISTANT TO... not-yet-due
Completed, but no date 2013-003934-33 A pilot phase II study with BRENTUXIMAB VEDOTIN as pre-ASCT induction therapy in relapsed/refractory Hodgkin’s lymphoma patients non responding to IGEV salvage treatment. bad-data
Ongoing 2013-003946-17 Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patients not-yet-due
Ongoing 2013-004014-17 Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem cell transplantation (... not-yet-due
Ongoing 2013-004109-24 A phase II study of Brentuximab Vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease not-yet-due
Ongoing 2013-005129-22 FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN –BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA’S PATIENTS AT FIRST RELAPSE not-yet-due
Ongoing 2014-005697-10 GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell non-Hodgkin’s lymphoma. not-yet-due